Skip to main content
. 2019 Jan 21;11(1):124. doi: 10.3390/cancers11010124

Figure 1.

Figure 1

Overall survival of patients with metastatic anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) according to TP53 status at baseline and progression. (A) The median overall survival (OS) was 44 months for patients with TP53 mutations at baseline (TP53mutbas) vs. 62 months for patients without TP53 mutations at baseline (TP53wtbas logrank p = 0.0182). (B) The median OS was 45 months for patients with initially wild-type status and detection of TP53 mutations in a subsequent biopsy (TP53mutconv) vs. 94 months for patients without subsequent detection of TP53 mutations (TP53wtprogr, logrank p = 0.0343). Treatment details are given in Table 1.